WO2015177153A1 - Endoprotéase spécifique de la proline - Google Patents

Endoprotéase spécifique de la proline Download PDF

Info

Publication number
WO2015177153A1
WO2015177153A1 PCT/EP2015/061002 EP2015061002W WO2015177153A1 WO 2015177153 A1 WO2015177153 A1 WO 2015177153A1 EP 2015061002 W EP2015061002 W EP 2015061002W WO 2015177153 A1 WO2015177153 A1 WO 2015177153A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
seq
nucleic acid
sequence
proline
Prior art date
Application number
PCT/EP2015/061002
Other languages
English (en)
Inventor
Jan Metske Van Der Laan
Peter Jozef Ida Van De Vondervoort
Chantal CHRISTIS
Martine SPAANS
Angela DE BRUINE-PAULUS
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of WO2015177153A1 publication Critical patent/WO2015177153A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
    • A23L2/84—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter using microorganisms or biological material, e.g. enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/26—Proteins
    • A21D2/267—Microbial proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus

Definitions

  • the present invention relates to a polypeptide having proline-specific endoprotease activity, a composition comprising the polypeptide, a nucleic acid encoding a proline-specific endoprotease, an expression vector comprising the nucleic acid encoding a proline-specific endoprotease, a recombinant host cell, a method for preparing proline-specific endoprotease and a process for preparing a food or feed product wherein the proline-specific endoprotease is used.
  • Proline-specific endoproteases are enzymes that hydrolyse a protein or peptide at a position where there is a proline in the protein or peptide.
  • a proline-specific endoprotease may for instance be derived from Aspergillus niger or Penicillium chrysogenum, such as disclosed in WO2002/046381 and WO2009/144269 respectively.
  • proline-specific endoproteases are known from WO2012/174127.
  • WO2012/174127 discloses proline-specific protease from Botryotinia, fuckeliana, Aspergillus clavatus, Sclerotinia sclerotiotum, Mycosphaerelly graminicola, Neuropspora crasse, Talaromyces stipitatus and Gibberella zeae.
  • Proline-specific endoprotease can be used in several applications, for instance in the degradation of gluten (see for instance WO2005/027953 or WO2003/068170).
  • Gluten is the insoluble protein fraction of cereals like wheat, rye, oat and barley.
  • Gluten is a complex mixture of glutenin- and prolamine molecules which are thought to cause toxic effects, for instance in patients suffering from celiac disease.
  • Celiac Sprue or celiac disease is considered to be an autoimmune disease. Patients suffering from Celiac Sprue need to follow a strict gluten-free diet, which is very difficult to follow because gluten is so widely used.
  • proline-specific endoprotease as a medicament or dietary supplement may alleviate the need for a strict gluten free diet (WO2003/068170).
  • Proline-specific endoproteases are also used for reducing haze in beer, wherein the proline-specific protease may be added during several stages of a beer production process for instance as disclosed in WO 2002/046381 or WO2007101888A2.
  • enzymes in food and feed applications have a suitable pH optimum and preferably are not active in the final food or beverage.
  • the aim of the present invention is an alternative proline-specific endoprotease with improved characteristics.
  • the present invention relates an isolated polypeptide having proline-specific endoprotease activity selected from the group consisting of
  • polypeptide comprising a mature polypeptide sequence of SEQ ID NO:
  • polypeptide that has least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %,
  • a polypeptide encoded by a nucleic acid that has at least 80%, 85%, 90%,
  • the present invention relates to a composition comprising a polypeptide as disclosed herein.
  • the present invention relates to a nucleic acid that has at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to a mature polypeptide coding sequence of SEQ ID NO: 1 .
  • the present invention also relates to an expression vector comprising a nucleic acid encoding a polypeptide according to the present invention.
  • the present invention relates to a host cell comprising a polynucleotide sequence, or an expression vector as disclosed herein.
  • the present invention relates to a method for the preparation of a polypeptide, comprising cultivating a host cell as disclosed herein, under conditions that allow expression of the polypeptide, and preparing the polypeptide.
  • the present invention relates to a process for the preparation of a food or feed product comprising incubating an intermediate form of the food or feed product with a polypeptide as disclosed herein, and preparing the food product.
  • the present invention also relates to a food or feed product obtainable by a process as disclosed herein.
  • baked products is herein defined as any product prepared from a dough or a batter.
  • the product may have a soft or a crisp character and may be of a white, light or dark type.
  • Baked products include, but are not limited to, bread such as for instance white, whole-meal or rye bread, French baguette-type bread, laminated dough products such as (Danish) pastry, croissants or puff pastry, pita bread, tortillas, tacos, cakes, pancakes, biscuits, cookies, doughnuts, bagels, pie crusts, muffins, steamed bread, and crisp bread,.
  • Types of baked products, methods to characterize and to produce them are known to those skilled in the art see for example "Baking Science and Technology", by E.J.
  • complementary strand can be used interchangeably with the term "complement”.
  • the complement of a nucleic acid strand can be the complement of a coding strand or the complement of a non-coding strand.
  • the complement of a nucleic acid encoding a polypeptide refers to the complementary strand of the strand encoding the amino acid sequence or to any nucleic acid molecule containing the same.
  • control sequence can be used interchangeably with the term "expression- regulating nucleic acid sequence”.
  • the term as used herein refers to nucleic acid sequences necessary for and/or affecting the expression of an operably linked coding sequence in a particular host organism or in vitro. When two nucleic acid sequences are operably linked, they usually will be in the same orientation and also in the same reading frame. They usually will be essentially contiguous, although this may not be required.
  • the expression-regulating nucleic acid sequences such as inter alia appropriate transcription initiation, termination, promoter, leader, signal peptide, propeptide, prepropeptide, or enhancer sequences; Shine-Dalgarno sequence, repressor or activator sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion, can be any nucleic acid sequence showing activity in the host organism of choice and can be derived from genes encoding proteins, which are either endogenous or heterologous to a host cell.
  • Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide.
  • the control sequence may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.
  • Control sequences may be optimized to their specific purpose.
  • a “dairy product” refers to any kind of milk-based product intended to be used as food, feed or beverage, including but not limited to cheese, milk, skimmed milk, acidified milk, butter milk, condensed milk, spreads, margarines, yoghurt, ice cream, milk powder, butter, EMC (Enzyme Modified cheese), dulce de leche, coffee whitener; coffee creamer, cream, ghee, dairy analogue, etcetera.
  • Cheese may be any kind of cheese, e.g. fresh cheese, hard cheese, curd cheese, cream cheese, white mould cheese, blue mould cheese and process cheese. Examples of fresh cheese are Ricotta, Cream cheese, Neufchatel or Cottage cheese.
  • Examples of hard cheese are Chester, Danbo, Manchego, Saint Paulin, Cheddar, Monterey, Colby, Edam, Gouda, Muenster, Swiss type, Gruyere, Emmenthaler, Personalgiano Reggiano, Grana Padano, Parmesan, Pecorino, Provolone, and Romano.
  • Examples of curd cheese such as Feta cheese, Quotija cheese, pasta filata cheese such as Mozzarella, and Queso fresco cheese.
  • Examples of cream cheese are Philadelphia cheese.
  • Examples of white mould cheese are Brie and Camembert cheese.
  • Examples of blue mould cheese are Gorgonzola and Danish blue cheese.
  • endopeptidases or endoproteinases are enzymes that are able to break peptide bonds of nonterminal amino acids (i.e. within the protein), in contrast to exopeptidases, which break peptide bonds either from the amino or the carboxyl terminus. Endopeptidases do not tend to break down peptides into monomers, but result in relatively large peptide fragments. The specific generation of relatively large fragments is highly preferred in many food and feed related applications. A particular case of endopeptidase is the oligopeptidase, whose substrates are oligopeptides instead of proteins.
  • expression includes any step involved in the production of the polypeptide including, but not limited to, transcription, post transcriptional modification, translation, post-translational modification, and secretion.
  • An expression vector comprises a polynucleotide coding for a polypeptide, operably linked to the appropriate control sequences (such as a promoter, and transcriptional and translational stop signals) for expression and/or translation in vitro, or in the host cell of the polynucleotide.
  • appropriate control sequences such as a promoter, and transcriptional and translational stop signals
  • the expression vector may be any vector (e.g., a plasmid or virus), which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the polynucleotide.
  • the choice of the vector will typically depend on the compatibility of the vector with the cell into which the vector is to be introduced.
  • the vectors may be linear or closed circular plasmids.
  • the vector may be an autonomously replicating vector, i.e. a vector, which exists as an extra-chromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extra-chromosomal element, a mini-chromosome, or an artificial chromosome.
  • the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
  • the integrative cloning vector may integrate at random or at a predetermined target locus in the chromosomes of the host cell.
  • the vector system may be a single vector or plasmid or two or more vectors or plasmids, which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
  • a host cell as defined herein is an organism suitable for genetic manipulation and one which may be cultured at cell densities useful for industrial production of a target product, such as a polypeptide according to the present invention.
  • a host cell may be a host cell found in nature or a host cell derived from a parent host cell after genetic manipulation or classical mutagenesis.
  • a host cell is a recombinant host cell.
  • a host cell may be a prokaryotic, archaebacterial or eukaryotic host cell.
  • a prokaryotic host cell may be, but is not limited to, a bacterial host cell.
  • An eukaryotic host cell may be, but is not limited to, a yeast, a fungus, an amoeba, an algae, a plant, an animal, or an insect host cell.
  • heterologous refers to nucleic acid or amino acid sequences not naturally occurring in a host cell. In other words, the nucleic acid or amino acid sequence is not identical to that naturally found in the host cell.
  • hybridization means the pairing of substantially complementary strands of oligomeric compounds, such as nucleic acid compounds.
  • Hybridization may be performed under low, medium or high stringency conditions.
  • Low stringency hybridization conditions comprise hybridizing in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1 % SDS at least at 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions).
  • Medium stringency hybridization conditions comprise hybridizing in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1 % SDS at 60°C
  • high stringency hybridization conditions comprise hybridizing in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1 % SDS at 65°C.
  • a nucleic acid or polynucleotide sequence is defined herein as a nucleotide polymer comprising at least 5 nucleotide or nucleic acid units.
  • a nucleotide or nucleic acid refers to RNA and DNA.
  • the terms "nucleic acid” and “polynucleotide sequence” are used interchangeably herein.
  • a “peptide” refers to a short chain of amino acid residues linked by a peptide (amide) bonds. The shortest peptide, a dipeptide, consists of 2 amino acids joined by single peptide bond.
  • polypeptide refers to a molecule comprising amino acid residues linked by peptide bonds and containing more than five amino acid residues.
  • protein as used herein is synonymous with the term “polypeptide” and may also refer to two or more polypeptides. Thus, the terms “protein” and “polypeptide” can be used interchangeably.
  • Polypeptides may optionally be modified (e.g., glycosylated, phosphorylated, acylated, farnesylated, prenylated, sulfonated, and the like) to add functionality.
  • Polypeptides exhibiting activity in the presence of a specific substrate under certain conditions may be referred to as enzymes. It will be understood that, as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding a given polypeptide may be produced.
  • isolated nucleic acid fragment is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.
  • isolated polypeptide as used herein means a polypeptide that is removed from at least one component, e.g. other polypeptide material, with which it is naturally associated.
  • the isolated polypeptide may be free of any other impurities.
  • the isolated polypeptide may be at least 50% pure, e.g., at least 60% pure, at least 70% pure, at least 75% pure, at least 80% pure, at least 85% pure, at least 80% pure, at least 90% pure, or at least 95% pure, 96%, 97%, 98%, 99%, 99.5%, 99.9% as determined by SDS-PAGE or any other analytical method suitable for this purpose and known to the person skilled in the art.
  • An isolated polypeptide may be produced by a recombinant host cell.
  • a "mature polypeptide” is defined herein as a polypeptide in its final form and is obtained after translation of a mRNA into polypeptide and post-translational modifications of said polypeptide.
  • Post-translational modification include N-terminal processing, C-terminal truncation, glycosylation, phosphorylation and removal of leader sequences such as signal peptides, propeptides and/or prepropeptides by cleavage.
  • a "mature polypeptide coding sequence” means a polynucleotide that encodes a mature polypeptide.
  • nucleic acid construct is herein referred to as a nucleic acid molecule, either single-or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature.
  • nucleic acid construct is synonymous with the term “expression cassette” when the nucleic acid construct contains all the control sequences required for expression of a coding sequence, wherein said control sequences are operably linked to said coding sequence.
  • a "proline-specific endoprotease” is a protease that hydrolyses a protein or peptide at a position where the protein or peptide contains a proline-residue.
  • a proline-specific endoprotease may have proline-specific endopotease and/or proline-specific oligopeptidase activity (EC3.4.21 .26).
  • a proline-specific endoprotease is preferably an enzyme that hydrolyses a peptide bond at the carboxy-terminal end of proline residues, resulting in a peptide and/or polypeptide fragment with a C-terminal proline..
  • promoter is defined herein as a DNA sequence that binds RNA polymerase and directs the polymerase to the correct downstream transcriptional start site of a nucleic acid sequence to initiate transcription.
  • recombinant when used in reference to a cell, nucleic acid, protein or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified.
  • recombinant cells express genes that are not found within the native (non- recombinant) form of the cell or express native genes that are otherwise abnormally expressed, underexpressed or not expressed at all.
  • the term “recombinant” is synonymous with “genetically modified” and "transgenic”.
  • Sequence identity is used interchangeable herein. For the purpose of this invention, it is defined here that in order to determine the percentage of sequence homology or sequence identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes. In order to optimize the alignment between the two sequences gaps may be introduced in any of the two sequences that are compared. Such alignment can be carried out over the full length of the sequences being compared. Alternatively, the alignment may be carried out over a shorter length, for example over about 20, about 50, about 100 or more nucleic acids/bases or amino acids.
  • the sequence identity is the percentage of identical matches between the two sequences over the reported aligned region.
  • the percent sequence identity between two amino acid sequences or between two nucleotide sequences may be determined using the Needleman and Wunsch algorithm for the alignment of two sequences. (Needleman, S. B. and Wunsch, C. D. (1970) J. Mol. Biol. 48, 443-453). Both amino acid sequences and nucleotide sequences can be aligned by the algorithm.
  • the Needleman-Wunsch algorithm has been implemented in the computer program NEEDLE.
  • the NEEDLE program from the EMBOSS package was used (version 2.8.0 or higher, EMBOSS: The European Molecular Biology Open Software Suite (2000) Rice, P. LongdenJ.
  • the percentage of sequence identity between a query sequence and a sequence of the invention is calculated as follows: Number of corresponding positions in the alignment showing an identical amino acid or identical nucleotide in both sequences divided by the total length of the alignment after subtraction of the total number of gaps in the alignment.
  • the identity as defined herein can be obtained from NEEDLE by using the NOBRIEF option and is labeled in the output of the program as "longest-identity".
  • the nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences.
  • Such searches can be performed using the N BLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403— 10.
  • Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17): 3389-3402.
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • polypeptides refers to a polypeptide preparation which contains at the most 50% by weight of other polypeptide material.
  • the polypeptides disclosed herein are preferably in a substantially pure form.
  • the polypeptides disclosed herein are in "essentially pure form", i.e. that the polypeptide preparation is essentially free of other polypeptide material.
  • the polypeptide may also be essentially free of non-polypeptide material such as nucleic acids, lipids, media components, and the like.
  • substantially pure polypeptide is synonymous with the terms “isolated polypeptide” and "polypeptide in isolated form”.
  • polynucleotide refers to a polynucleotide preparation which contains at the most 50% by weight of other polynucleotide material.
  • the polynucleotides disclosed herein are preferably in a substantially pure form.
  • the polynucleotide disclosed herein are in "essentially pure form", i.e. that the polynucleotide preparation is essentially free of other polynucleotide material.
  • the polynucleotide may also be essentially free of non-polynucleotide material such as polypeptides, lipids, media components, and the like.
  • substantially pure polynucleotide is synonymous with the terms “isolated polynucleotide” and "polynucleotide in isolated form”.
  • a "synthetic molecule”, such as a synthetic nucleic acid or a synthetic polypeptide is produced by in vitro chemical or enzymatic synthesis. It includes, but is not limited to, variant nucleic acids made with optimal codon usage for host organisms of choice.
  • a synthetic nucleic acid may be optimized for codon use, preferably according to the methods described in WO2006/077258 and/or WO2008000632, which are herein incorporated by reference.
  • WO2008/000632 addresses codon-pair optimization.
  • Codon-pair optimization is a method wherein the nucleotide sequences encoding a polypeptide that have been modified with respect to their codon-usage, in particular the codon-pairs that are used, are optimized to obtain improved expression of the nucleotide sequence encoding the polypeptide and/or improved production of the encoded polypeptide.
  • Codon pairs are defined as a set of two subsequent triplets (codons) in a coding sequence.
  • variants can be used interchangeably. They can refer to either polypeptides or nucleic acids. Variants include substitutions, insertions, deletions, truncations, transversions, and/or inversions, at one or more locations relative to a reference sequence. Variants can be made for example by site-saturation mutagenesis, scanning mutagenesis, insertional mutagenesis, random mutagenesis, site-directed mutagenesis, and directed-evolution, as well as various other recombination approaches known to a skilled person in the art. Variant genes of nucleic acids may be synthesized artificially by known techniques in the art.
  • FIG. 1 pGBTOP-16 vector used for cloning of the GLA gene.
  • the pGBTOP-16 vector is derived from the pGBTOP-12 vector described in WO 201 1/009700. In addition to pGBTOP-12, it contains the ccdB gene from E. coli for positive selection for presence of an insert between the EcoRI and Pad cloning sites. The Pad restriction site replaces the SnaBI restriction site present in pGBTOP-12. This vector is linearized by Notl digestion prior to transformation.
  • Figure 2 Alignment of proline-specific endoprotease polypeptide sequences of SEQ ID NO: 2 and 7 derived from Aspergillus aculeatus.
  • the present invention relates to a polypeptide having proline- specific endoprotease activity, selected from the group consisting of
  • polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2; ii. a polypeptide that has least 80%, 85%, 86%, 87%, 88%, 89%, 90%,
  • a polypeptide encoded by a nucleic acid that has at least 80%, 85%,
  • the present invention relates to a polypeptide that is an isolated, substantially pure, pure, recombinant, synthetic or variant polypeptide of the polypeptide as disclosed herein.
  • the present invention relates an isolated polypeptide having proline-specific endoprotease activity comprising the amino acid sequence of SEQ ID NO: 2.
  • a proline-specific endoprotease as disclosed herein may be derived from Aspergillus aculeatus.
  • the wording "derived” or “derivable” from with respect to the origin of a polypeptide as disclosed herein, means that when carrying out a BLAST search with a polypeptide according to the present invention, the polypeptide according to the present invention may be derivable from a natural source, such as a microbial cell, of which an endogenous polypeptide shows the highest percentage homology or identity with the polypeptide as disclosed herein.
  • a polypeptide as disclosed herein has an improved property as compared to a proline-specific endoprotease known in the art.
  • An improved property may be a reduced activity of a polypeptide provided by the invention after pasteurization, such as pasteurization that is applied in the preparation of a food product.
  • a reduced activity may be less than 80%, or less than 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 30%, 20%, 10% of the proline-specific endoprotease activity remains after pasteurizing the polypeptide as compared to a polypeptide of the invention that has not been submitted to pasteurization.
  • a proline-specific endoprotease as disclosed herein can be readily used in food applications, since there is a desire by the food industry that no active enzyme remains in the final food product.
  • An improved property of a polypeptide having proline-specific endoprotease may also be an increased thermostability, or an increased specific activity at specific temperatures and pH values.
  • a polypeptide provided by the invention may be a polypeptide that has least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2, or of SEQ ID NO: 7.
  • a polypeptide according to SEQ ID NO: 2 comprises a pre-pro- sequence.
  • the pre- pro-sequence such as amino acids 1 to 30, 1 to 31 , 1 to 32, 1 to 33, 1 to 34, 1 to 35, 1 to 36, 1 to 37, 1 to 38, 1 to 39, 1 to 40, 1 to 41 of SEQ I D NO: 2 are removed.
  • the mature polypeptide sequence having proline-specific endoprotease activity of SEQ ID NO:2 may comprise amino acids 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, or 45 to amino acid 512, 513, 514, 515, 516, 517, 518, 519, 520 or 521 of SEQ ID NO:2, wherein the amino acid methionine at position 1 in SEQ ID NO: 2 is counted as number 1 .
  • the mature polypeptide sequence having proline-specific endoprotease activity comprises amino acids 37 to 521 of SEQ ID NO:2, wherein the amino acid methionine at position 1 in SEQ ID NO: 2 is counted as number 1 .
  • a polypeptide according to the present invention may be encoded by any suitable polynucleotide sequence.
  • a polynucleotide sequence is codon optimized, or a codon pair optimized sequence for expression of a polypeptide as disclosed herein in a particular host cell.
  • a polypeptide as disclosed herein may be encoded by a polynucleotide that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1 or of SEQ ID NO: 8.
  • SEQ ID NO: 1 and SEQ ID NO: 8 are a codon optimized polynucleotide sequences for expression of a polypeptide as disclosed herein in an Aspergillus niger host cell.
  • a polypeptide as disclosed herein may also be encoded by a nucleic acid that has at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to a mature polypeptide coding sequence of SEQ ID NO: 1 .
  • a polypeptide having proline-specific endoprotease activity as disclosed herein may also be a variant of a mature polypeptide of SEQ ID NO: 2, comprising a substitution, deletion and/or insertion at one or more positions of the mature polypeptide SEQ ID NO: 2.
  • a variant of the mature polypeptide of SEQ ID NO:2 may be an amino acid sequence that differs in 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12 amino acids from the amino acids of of the mature polypeptide of SEQ ID NO:2.
  • a variant of the mature polypeptide of SEQ ID NO: 2 may be a polypeptide, which, when aligned with SEQ ID NO: 2, comprises at least one mutation at position 37, 38, 39, 40, 42, 43, and / or position 156, and / or an insertion after position 156, wherein methionine (M) at position in 1 in SEQ ID NO: 2 is counted as 1 .
  • a variant of the mature polypeptide as disclosed herein may, when aligned with SEQ ID NO: 2, comprise at least one amino acid substitution corresponding to serine (S) at position 37, serine (S) at position 38, valine (V) at position 39, valine (V) at position 40, serine at position 42, threonine (T) at position 43, and / or alanine (A) at position 156, and / or an insertion of an arginine (R) after position 156, wherein methionine (M) at position in 1 in SEQ ID NO: 2 is counted as 1
  • a polypeptide having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, identity to the mature polypeptide sequence of SEQ ID NO: 2, may be a polypeptide, which, when aligned with SEQ ID NO: 2, comprises at least one mutation at position 37, 38, 39, 40, 42, 43, 156, and / or an insertion after position 156, wherein methionine (M) at position in 1 in SEQ ID NO: 2 is counted as 1.
  • a polypeptide as disclosed herein may, when aligned with SEQ ID NO: 2, comprise at least one amino acid substitution corresponding to serine (S) at position 37, serine (S) at position 38, valine (V) at position 39, valine (V) at position 40, serine at position 42, threonine (T) at position 43, and / or alanine (A) at position 156, and / or an insertion of an arginine (R) after position 156, wherein methionine (M) at position in 1 in SEQ ID NO: 2 is counted as 1 .
  • the present invention features a biologically active fragment of a polypeptide as disclosed herein.
  • Biologically active fragments of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the proline-specific endoprotease protein (e.g., the mature amino acid sequence of SEQ ID NO:2), which include fewer amino acids than the full length protein but which exhibits at least one biological activity of the corresponding full-length protein.
  • biologically active fragments comprise a domain or motif with at least one activity of the proline-specific endoprotease protein.
  • a biologically active fragment may for instance comprise a catalytic domain.
  • a biologically active fragment of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.
  • other biologically active portions, in which other regions of the protein are deleted can be prepared by recombinant techniques and evaluated for one or more of the biological activities of the native form of a polypeptide of the invention.
  • the invention also features nucleic acid fragments which encode the above biologically active fragments of the proline-specific endoprotease protein.
  • a polypeptide according to the present invention may be a fusion protein.
  • Techniques for producing fusion polypeptides are known in the art, and include ligating the coding sequences encoding the polypeptides so that they are in frame. Expression of the fused polypeptide is under control of the same promoter (s) and terminator.
  • the hybrid polypeptides may comprise a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides wherein one or more may be heterologous to a host cell.
  • Such fusion polypeptides from at least two different polypeptides may comprise a binding domain from one polypeptide, operably linked to a catalytic domain from a second polypeptide . Examples of fusion polypeptides and signal sequence fusions are for example as described in WO2010/121933, WO2013/007820 and WO2013/007821.
  • a polypeptide according to the present invention may be derived from any suitable eukaryotic.
  • a eukaryotic cell may be a mammalian, insect, plant, fungal, or algal cell.
  • a polypeptide according to the present invention may also be derived from a filamentous fungal cell or thermophilic filamentous fungal cell.
  • Preferred filamentous fungal cells belong to a species of an Acremonium, Aspergillus, Chrysosporium, Myceliophthora, Penicillium, Talaromyces, Rasamsonia, Thielavia, Fusarium or Trichoderma, Amorphotheca, Pseudocercosporella, Trametes, Rhizomucor, Calcarisporiella, Thermomyces, Thermoascus, Cornyascus, Myricoccum, Scytalidium, Chaetomium, Paecilomyces, Corynascus, Malbranchea, Stilbella, Thermomyces, Dactylomyces , Humicola, Chaetomium, Melanocarpus, Rhizomucor, Lentinula, Anaeromyces genus, and
  • a polypeptide according to the present invention may be a naturally occurring polypeptide or a genetically modified or recombinant polypeptide.
  • a polypeptide as disclosed herein may be purified. Purification of protein is known to a skilled person in the art
  • the present invention relates to a composition comprising a polypeptide as disclosed herein.
  • a composition as disclosed herein may comprise a carrier, an excipient, an auxiliary enzyme, or other compounds.
  • a composition, or a formulation comprises a compound with which a proline-specific endoprotease may be formulated.
  • An excipient as used herein is an inactive substance formulated alongside with a polypeptide as disclosed herein, for instance sucrose or lactose, glycerol, sorbitol or sodium chloride.
  • a composition comprising a polypeptide as disclosed herein may be a liquid composition or a solid composition.
  • a liquid composition usually comprises water.
  • the composition When formulated as a liquid composition, the composition usually comprises components that lower the water activity, such as glycerol, sorbitol or sodium chloride (NaCI).
  • a solid composition comprising a polypeptide as disclosed herein may comprise a granulate comprising the enzyme or the composition comprises an encapsulated polypeptide in liquid matrices like liposomes or gels like alginate or carrageenans.
  • a composition as disclosed herein may also comprise a carrier comprising a polypeptide as disclosed herein.
  • a polypeptide as disclosed herein may be bound or immobilized to a carrier by known technologies in the art.
  • the present invention also relates to a process for preparing a composition comprising a polypeptide as disclosed herein, which may comprise spray drying a fermentation medium comprising the polypeptide, or granulating, or encapsulating a polypeptide as disclosed herein, and preparing the composition.
  • the present invention relates to a polynucleotide sequence encoding a polypeptide as disclosed herein, which has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1 , or to the mature polypeptide coding sequence of SEQ ID NO:1 .
  • a polynucleotide sequence as disclosed herein may comprise SEQ I D NO: 1 or SEQ I D NO: 8, or may comprise the mature polypeptide coding sequence of SEQ ID NO:1 or of SEQ ID NO: 8.
  • nucleic acid is disclosed that is an isolated, substantially pure, pure, recombinant, synthetic or variant nucleic acid of the nucleic acid of SEQ ID NO: 1 .
  • a variant nucleic acid sequence may for instance have at least 80% sequence identity to SEQ ID NO:1 .
  • the present invention relates to an expression vector comprising a polynucleotide as disclosed herein operably linked to one or more control sequence(s) that direct expression of the polypeptide in an expression host cell.
  • nucleic acid constructs there are several ways of inserting a nucleic acid into a nucleic acid construct or an expression vector which are known to a skilled person in the art, see for instance Sambrook & Russell, Molecular Cloning: A Laboratory Manual, 3rd Ed., CSHL Press, Cold Spring Harbor, NY, 2001 . It may be desirable to manipulate a nucleic acid encoding a polypeptide of the present invention with control sequences, such as promoter and terminator sequences.
  • a promoter may be any appropriate promoter sequence suitable for a eukaryotic or prokaryotic host cell, which shows transcriptional activity, including mutant, truncated, and hybrid promoters, and may be obtained from polynucleotides encoding extracellular or intracellular polypeptides either endogenous (native) or heterologous (foreign) to the cell.
  • the promoter may be a constitutive or inducible promoter.
  • the promoter is an inducible promoter, for instance a starch inducible promoter.
  • Promoters suitable in filamentous fungi are promoters which may be selected from the group, which includes but is not limited to promoters obtained from the polynucleotides encoding A.
  • oryzae TAKA amylase Rhizomucor miehei aspartic proteinase, Aspergillus gpdA promoter, A. niger neutral alpha-amylase, A. niger acid stable alpha-amylase, A. niger or A. awamori glucoamylase (glaA), A. niger or A. awamori endoxylanase (xlnA) or beta-xylosidase (x/nD), T. reesei cellobiohydrolase I (CBHI), R. miehei lipase, A. oryzae alkaline protease, A. oryzae triose phosphate isomerase, A.
  • Trichoderma reesei beta-glucosidase Trichoderma reesei cellobiohydrolase I, Trichoderma reesei cellobiohydrolase II, Trichoderma reesei endoglucanase I, Trichoderma reesei endoglucanase II, Trichoderma reesei endoglucanase III, Trichoderma reesei endoglucanase IV, Trichoderma reesei endoglucanase V, Trichoderma reesese
  • any terminator which is functional in a cell as disclosed herein may be used, which are known to a skilled person in the art.
  • suitable terminator sequences in filamentous fungi include terminator sequences of a filamentous fungal gene, such as from Aspergillus genes, for instance from the gene A. oryzae TAKA amylase, the genes encoding A. niger glucoamylase (glaA), A. nidulans anthranilate synthase, A. niger alpha-glucosidase, trpC and/or Fusarium oxysporum trypsin-like protease.
  • Aspergillus genes for instance from the gene A. oryzae TAKA amylase
  • glaA A. nidulans anthranilate synthase
  • A. niger alpha-glucosidase trpC and/or Fusarium oxysporum trypsin-like protease
  • the present invention relates to a host cell comprising a nucleic acid construct or an expression vector as disclosed herein.
  • a suitable host cell may be a mammalian, insect, plant, fungal, or algal cell, or a bacterial cell.
  • a suitable host cell may be a fungal cell, for instance from the genus Acremonium, Aspergillus, Chrysosporium, Fusarium, Myceliophthora, Penicillium, Rasamsonia, Talaromyces, Thielavia, Trichoderma, Saccaromyces, Kluyveromyces, Pichia, for instance Aspergillus niger, Aspergillus awamori, Aspergillus foetidus, A.
  • a host cell may be a recombinant or transgenic host cell.
  • the host cell may be genetically modified with a nucleic acid construct or expression vector as disclosed herein with standard techniques known in the art, such as electroporation, protoplast transformation or conjugation for instance as disclosed in Sambrook & Russell, Molecular Cloning: A Laboratory Manual, 3rd Ed., CSHL Press, Cold Spring Harbor, NY, 2001 .
  • the present invention relates to a process for the production of a polypeptide as disclosed herein comprising cultivating a host cell in a suitable fermentation medium under conditions conducive to the production of the polypeptide and producing the polypeptide.
  • a host cell used such as pH, temperature and composition of a fermentation medium.
  • Host cells can be cultivated in shake flasks, or in fermenters having a volume of 0.5 or 1 litre or larger to 10 to 100 or more cubic metres. Cultivation may be performed aerobically or anaerobically depending on the requirements of a host cell.
  • polypeptide as disclosed herein is recovered or isolated from the fermentation medium.
  • a polypeptide having proline-specific endoprotease activity or a composition comprising a polypeptide as disclosed herein may be used in a large variety of applications, for instance in the production of a food or feed product, such as in the production of a protein hydrolysate.
  • a food or feed product such as in the production of a protein hydrolysate.
  • Several food proteins contain highly allergenic subfractions which may be even toxic to specific individuals, such as gluten that contains prolamines with proline-rich peptide sequences. These proteins can be subjected to the new enzyme to alleviate their antigenicity or toxicity.
  • Celiac Sprue also known as celiac disease, is an autoimmune disease of the small intestine caused by the ingestion of gluten proteins from cereals, such as alpha- gliadin from wheat, hordein from barley, secalin from rye and avenin from oats.
  • a polypeptide having proline-specific endoprotease activity or a composition comprising a polypeptide as disclosed herein may be used in the preparation of a dietary supplement or as a medicament in the treatment of a patient suffering from Celiac Sprue, or in the treatment of gluten intolerant people.
  • a polypeptide as disclosed herein may also be used as a processing aid to hydrolyse gluten in a food product.
  • the present invention relates to a process for the preparation of a food or feed product comprising incubating an intermediate form of a food or feed product with a polypeptide or composition comprising the polypeptide as disclosed herein and preparing the food or feed product.
  • a food product in a process as disclosed herein includes a beverage, such as beer, wine or fruit juice, or a baked product, or a dairy product, but is not limited thereto.
  • a food product and / or an intermediate form of a food product may comprise gluten.
  • polypeptide having proline-specific endoprotease activity as disclosed herein was capable of hydrolysing the toxic epitopes in gluten into nontoxic fragments.
  • An intermediate form of a food product may be any suitable form of a food product during the preparation of the food product.
  • an intermediate form of beer may be a mash and an intermediate form of bread may be a dough or a batter.
  • a process for the preparation of a food product according to the present disclosure may comprise a step of pasteurizing the food product.
  • Pasteurization usually comprises heating a food product, or an intermediate form of a food product, for instance by bringing the food product or intermediate form of a food product to a temperature of between 60 to 68°C between 10 to 20 min, or between 12 and 18 min, or to a temperature of between 70-74°C, such as about 72 °C for at least 5, 10 or 15 seconds.
  • a food product in a process as disclosed herein may also be a protein hydrolysate. Accordingly, the present disclosure relates to a process for the preparation of a protein hydrolysate, comprising contacting a protein substrate with a polypeptide or a composition as disclosed herein, and producing the protein hydrolysate.
  • a protein hydrolysate may be prepared from any suitable a protein substrate, for instance a protein substrate that is rich in proline residues, such as gluten in cereals or caseins in bovine milk.
  • the present invention relates to a food product obtainable by a process for the preparation of a food product as disclosed herein.
  • the protein sequence of a proline-specific endoprotease (PEP) derived from Aspergillus aculeatus is shown in SEQ ID NO: 2 and called BC2G076.
  • the first part of SEQ ID NO: 2 comprises 17 amino acids of a signal sequence of pectinmethylesterase of A. niger (PMeA ss; SEQ ID NO: 3) for efficient secretion in Aspergillus niger.
  • the following part comprises 19 amino acids of a prosequence of A. niger proline specific endoprotease (SEQ ID NO: 4).
  • a second protein sequence of a proline-specific endoprotease derived from A. aculeatus is shown in SEQ ID NO: 7, which is 527 amino acids long. The first 41 amino acids are estimated to encode a preprosequence.
  • the PEP of SEQ ID NO: 7 is called BC2G1 12.
  • the codon optimized DNA sequence for A. niger of the gene encoding the PEP protein of SEQ ID: NO: 2 is shown in SEQ ID NO: 1 .
  • the codon optimized DNA sequence for A. niger of the gene encoding the PEP protein of SEQ ID: NO: 7 is shown in SEQ ID NO: 8.
  • the translational initiation sequence of the glucoamylase glaA promoter was modified into 5'-CACCGTCAAA ATG-3' and an optimal translational termination sequence 5'-TAAA-3' was used in the generation of the expression construct (as also detailed in WO2006/077258).
  • a DNA fragment containing a.o. part of the glucoamylase promoter and the PEP encoding gene was synthesized completely, purified and digested with EcoRI and Pad.
  • the pGBTOP-16 vector ( Figure 1 ) was linearized by EcoRI/Pacl digestion and the linearized vector fragment was subsequently purified by gel-extraction.
  • the DNA fragment containing the PEP coding region is cloned into the pGBTOP-16 vector resulting in pGBTOP-PEP.
  • A. niger GBA 306 (Ag/aA, ApepA, AhdfA, adapted Bam ⁇ amplicon, AamyBII, AamyBI, amyA alpha-amylase and glucoamylase negative strain) was transformed with linearized pGBTOP-PEP vector by ⁇ / ⁇ -digestion, in a co-transformation protocol with linearized pGBAAS-4, with strain and methods as described in WO 201 1/009700 and references therein, and selected on acetamide containing media and colony purified according to standard procedures.
  • Transformation and selection was performed as described in WO 98/46772 and WO 99/32617.
  • Strains containing the PEP gene were selected via PCR with primers specific for the PEP gene to verify presence of the pGBTOP-PEP expression cassette.
  • a single transformant was selected, named PEP1A (BC2G076) and PEP1 B (BC2G1 12), and further replica- plated to obtain a single strain inoculum.
  • Example 1.2 Production of PEP BC2G076 and PEP BC2G112 in A. niger PEP1 -A and PEP1 -B strains
  • Fresh A. niger PEP-1 A and PEP-1 B spores were prepared. 4 shake flasks with 100 ml fermentation medium 1 (10 % w/v Corn Steep Solids, 1 % w/v glucose. H 2 0, 0.1 % w/v NaH 2 P0 4 .H 2 0, 0.05 % w/v MgS0 4 .7H 2 Q, 0.025 % w/v Basildon, pH 5.8) in 500 ml shake flasks with baffle were inoculated with 10 7 spores. These pre-cultures were incubated at 34 °C and 170 rpm for 16-24 hours.
  • 100 ml fermentation medium 1 (10 % w/v Corn Steep Solids, 1 % w/v glucose. H 2 0, 0.1 % w/v NaH 2 P0 4 .H 2 0, 0.05 % w/v MgS0 4 .7H 2 Q, 0.025 % w/v Basildon, pH
  • Example 1.3 Production of the reference proline-specific endoprotease from A. niger
  • the proline-specific endoprotease from A. niger is known from WO2002/046381 .
  • the protein sequence of proline-specific endoprotease (PEP) from A. niger is shown in SEQ ID NO: 5, wherein the first 17 amino acids are a signal sequence of pectinemethylesterase of A. niger (PMeA ss; SEQ ID NO: 3) and the following part comprises 19 amino acids of the prosequence of A. niger proline specific endoprotease (SEQ ID NO:4).
  • the blank was prepared by mixing the diluted culture supernatant with the substrate solution which had been mixed with the HCI solution beforehand.
  • the activity is expressed in pNASU's.
  • 1 pNASU is the amount of enzyme which liberates from Ac-AAP-pNA in 1 hour the amount of pNA that corresponds to an increase in absorption at 405 nm of 1 OD, using the conditions as described above.
  • the A405 should not be below the blank value at the start of the reaction, or above 2.5 at the end of the reaction, nor may the A405 exceed the linear range of the spectrophotometer that is used.
  • the culture supernatant of PEP1 -B strains containing PEP BC2G1 12 and the Ac-AAP-pNA substrate were both diluted in buffers ranging from pH 3.5 to pH 7 (0.1 M citric acid/Na 2 HP0 4 , with 50 mM NaCI). Subsequently, 100 ⁇ _ of the diluted supernatant was mixed with 100 ⁇ _ of the 6 mM Ac-AAP-pNA substrate solution in a 96 wells flat bottom MTP. The reaction was stopped after 60 min at 20 ° C with addition of 40 ⁇ _ 1 M NaOH.
  • the activity of the PEP was measured by the increase in absorbance at 405 nm.
  • the supernatant was removed and the pellet was dissolved in 50 ⁇ 50 mM NaOH (Sigma-Aldrich, Netherlands) and then 350 ⁇ 100 mM NH4HC03 (Sigma-Aldrich, Netherlands) was added. Then 200 ⁇ of the sample was reduced and alkylated. For reduction, 5 ⁇ TCEP (Sigma-Aldrich, Netherlands) was added to the solution and incubated at room temperature in a thermomixer at 1000 rpm for 30 min. For the alkylation 5 ⁇ of 550 mM IAA (lodoacetamide, Sigma-Aldrich, Netherlands) was added and incubated in a thermomixer at 1000 rpm in the dark for 30 min.
  • the sample was analyzed on the Acquity l-class - Synapt G2-S (Waters, UK), with the following parameters: column: Waters Acquity UPLC BEH300 C4 1 .7 ⁇ 300A pore size 2.1 *50 mm; column temperature: 75 °C; injection volume: 1 ⁇ ; mobile phase A: Formic Acid 0,1 % in Mili-Q (Biosolve, Netherlands); mobile phase B: Formic Acid 0,1 % in Acetonitrile (Biosolve, Netherlands). A 15 minutes gradient was applied to the column by varying phase A and B (from 20 to 50 % B).
  • the MS detector settings were: acquisition mass range 500-3500 m/z, scan time 1 sec, positive ESI, TOF MS Resolution mode, with data correction using Leu-Enk (Sigma-Aldrich, Netherlands) as lock mass on the fly during the run.
  • the mass spectrum shows a peak at 54149 Da.
  • the observed mass corresponds to amino acids 37-521 of SEQ ID NO 2.
  • the N- terminus of the major species in the mature PEP BC2G076 sample starts at ATTGEAY.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à un polypeptide ayant une activité d'endoprotéase spécifique de la proline, choisi dans le groupe constitué par i. un polypeptide comprenant une séquence de polypeptide mature de SEQ ID NO : 2 ; ii. un polypeptide qui a une identité d'au moins 80 %, 85 %, 86 %, 87 %, 88 %, 89 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 % ou 99 % d'avec la séquence de polypeptide mature SEQ ID NO : 2; iii. un polypeptide codé par un acide nucléique qui s'hybride dans des conditions de stringence moyenne, de préférence dans des conditions de stringence élevée, avec le brin complémentaire de la séquence codant pour le polypeptide mature de SEQ ID NO : 1 ; et iv. un polypeptide codé par un acide nucléique qui a une identité d'au moins 80 %, 85 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % ou 100 % avec la séquence codant pour le polypeptide mature de SEQ ID NO : 1. L'invention se rapporte en outre à un procédé de production du polypeptide et à un procédé pour la préparation d'un produit alimentaire ou aliment pour animaux dans lequel le polypeptide est utilisé.
PCT/EP2015/061002 2014-05-19 2015-05-19 Endoprotéase spécifique de la proline WO2015177153A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14168864.8 2014-05-19
EP14168864 2014-05-19

Publications (1)

Publication Number Publication Date
WO2015177153A1 true WO2015177153A1 (fr) 2015-11-26

Family

ID=50732002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/061002 WO2015177153A1 (fr) 2014-05-19 2015-05-19 Endoprotéase spécifique de la proline

Country Status (1)

Country Link
WO (1) WO2015177153A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019185600A1 (fr) * 2018-03-29 2019-10-03 Dsm Ip Assets B.V. Procédé de préparation d'une boisson stable
CN116854796A (zh) * 2023-09-05 2023-10-10 中国农业大学 一种醇溶蛋白改性方法及其应用

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000787A1 (fr) 1994-06-30 1996-01-11 Novo Nordisk Biotech, Inc. Systeme d'expression de fusarium non pathogene, non toxicogene, non toxique, et promoteurs et terminateurs utilises dans ce systeme
WO1998046772A2 (fr) 1997-04-11 1998-10-22 Dsm N.V. Transformation genetique comme outil pour la construction de champignons filamenteux industriels de recombinaison
WO1999032617A2 (fr) 1997-12-22 1999-07-01 Dsm N.V. Clonage d'expression dans les champignons filamenteux
WO2000056900A2 (fr) 1999-03-22 2000-09-28 Novo Nordisk Biotech, Inc. Promoteurs exprimant les genes d'une cellule fongique
WO2002046381A2 (fr) 2000-12-07 2002-06-13 Dsm N.V. Procede empechant ou reduisant le trouble dans des boissons
WO2003068170A2 (fr) 2002-02-14 2003-08-21 The Board Of Trustees Of The Leland Stanford Junior University Traitement de denrees alimentaires aux enzymes contre l'enteropathie au gluten
WO2003104382A1 (fr) * 2002-06-07 2003-12-18 Dsm Ip Assets B.V. Procede ameliore permettant de prevenir ou de limiter la turbidite de boissons
WO2005027953A2 (fr) 2003-09-23 2005-03-31 Dsm Ip Assets B.V. Utilisation d'endoproteases specifiques de la proline pour l'hydrolyse de peptides et de proteines
WO2006077258A1 (fr) 2005-01-24 2006-07-27 Dsm Ip Assets B.V. Procede de fabrication d'un compose d'interet dans une cellule fongique filamenteuse
WO2007101888A2 (fr) 2006-07-13 2007-09-13 Dsm Ip Assets B.V. Procede de brassage ameliore
WO2008000632A1 (fr) 2006-06-29 2008-01-03 Dsm Ip Assets B.V. Procédé pour obtenir une expression de polypeptides améliorée
WO2009144269A1 (fr) 2008-05-30 2009-12-03 Dsm Ip Assets B.V. Protéase spécifique de la proline à partir de penicillium chrysogenum
WO2010121933A1 (fr) 2009-04-22 2010-10-28 Dsm Ip Assets B.V. Procédé de production d'un polypeptide recombinant d'intérêt
WO2011009700A1 (fr) 2009-07-22 2011-01-27 Dsm Ip Assets B.V. Cellule hôte améliorée destinée à la production d'un composé intéressant
WO2012174127A1 (fr) 2011-06-17 2012-12-20 Alvine Pharmaceuticals, Inc. Protéases destinées à dégrader le gluten
WO2013007821A1 (fr) 2011-07-14 2013-01-17 Dsm Ip Assets B.V. Procédé de criblage

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000787A1 (fr) 1994-06-30 1996-01-11 Novo Nordisk Biotech, Inc. Systeme d'expression de fusarium non pathogene, non toxicogene, non toxique, et promoteurs et terminateurs utilises dans ce systeme
WO1998046772A2 (fr) 1997-04-11 1998-10-22 Dsm N.V. Transformation genetique comme outil pour la construction de champignons filamenteux industriels de recombinaison
WO1999032617A2 (fr) 1997-12-22 1999-07-01 Dsm N.V. Clonage d'expression dans les champignons filamenteux
WO2000056900A2 (fr) 1999-03-22 2000-09-28 Novo Nordisk Biotech, Inc. Promoteurs exprimant les genes d'une cellule fongique
WO2002046381A2 (fr) 2000-12-07 2002-06-13 Dsm N.V. Procede empechant ou reduisant le trouble dans des boissons
WO2003068170A2 (fr) 2002-02-14 2003-08-21 The Board Of Trustees Of The Leland Stanford Junior University Traitement de denrees alimentaires aux enzymes contre l'enteropathie au gluten
WO2003104382A1 (fr) * 2002-06-07 2003-12-18 Dsm Ip Assets B.V. Procede ameliore permettant de prevenir ou de limiter la turbidite de boissons
WO2005027953A2 (fr) 2003-09-23 2005-03-31 Dsm Ip Assets B.V. Utilisation d'endoproteases specifiques de la proline pour l'hydrolyse de peptides et de proteines
WO2006077258A1 (fr) 2005-01-24 2006-07-27 Dsm Ip Assets B.V. Procede de fabrication d'un compose d'interet dans une cellule fongique filamenteuse
WO2008000632A1 (fr) 2006-06-29 2008-01-03 Dsm Ip Assets B.V. Procédé pour obtenir une expression de polypeptides améliorée
WO2007101888A2 (fr) 2006-07-13 2007-09-13 Dsm Ip Assets B.V. Procede de brassage ameliore
WO2009144269A1 (fr) 2008-05-30 2009-12-03 Dsm Ip Assets B.V. Protéase spécifique de la proline à partir de penicillium chrysogenum
WO2010121933A1 (fr) 2009-04-22 2010-10-28 Dsm Ip Assets B.V. Procédé de production d'un polypeptide recombinant d'intérêt
WO2011009700A1 (fr) 2009-07-22 2011-01-27 Dsm Ip Assets B.V. Cellule hôte améliorée destinée à la production d'un composé intéressant
WO2012174127A1 (fr) 2011-06-17 2012-12-20 Alvine Pharmaceuticals, Inc. Protéases destinées à dégrader le gluten
WO2013007821A1 (fr) 2011-07-14 2013-01-17 Dsm Ip Assets B.V. Procédé de criblage
WO2013007820A1 (fr) 2011-07-14 2013-01-17 Dsm Ip Assets B.V. Procédé de criblage

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402
E.J. PYLER; L.A. GORTON: "Baking Science and Technology", vol. 2, 2008, SOSLAND PUBLISHING COMPANY
G.M.H. MEESTERS: "Encapsulation of Enzymes and Peptides", 2010, article "Encapsulation Technologies for Active Food Ingredients and food processing"
NEEDLEMAN, S. B.; WUNSCH, C. D., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
RICE,P; LONGDEN.I.; BLEASBY,A: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS IN GENETICS, vol. 16, no. 6, 2000, pages 276 - 277, Retrieved from the Internet <URL:http://emboss.bioinformatics.nl>
S.P. CAUVAIN; L.S. YOUNG: "Baked Products: Science, Technology and Practice", 2006, BLACKWELL PUBLISHING LTD
SAMBROOK; RUSSELL: "Molecular Cloning: A Laboratory Manual", 2001, CSHL PRESS
STEPNIAK DARIUSZ ET AL: "Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease", AMERICAN JOURNAL OF PHYSIOLOGY - GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 291, no. 4, October 2006 (2006-10-01), pages G621 - G629, XP002741636 *
THERESA WALTER: "Degradation of Gluten in Wheat Bran and Bread Drink by Means of a Proline-Specific Peptidase", JOURNAL OF NUTRITION & FOOD SCIENCES, vol. 04, no. 05, 1 January 2014 (2014-01-01), XP055199463, DOI: 10.4172/2155-9600.1000293 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019185600A1 (fr) * 2018-03-29 2019-10-03 Dsm Ip Assets B.V. Procédé de préparation d'une boisson stable
US11578292B2 (en) 2018-03-29 2023-02-14 Dsm Ip Assets B.V. Process for the preparation of a stable beverage
CN116854796A (zh) * 2023-09-05 2023-10-10 中国农业大学 一种醇溶蛋白改性方法及其应用
CN116854796B (zh) * 2023-09-05 2023-11-28 中国农业大学 一种醇溶蛋白改性方法及其应用

Similar Documents

Publication Publication Date Title
Yegin et al. Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering
EP3152305B1 (fr) Endoprotéase spécifique de la proline et son utilisation
JP2008526202A (ja) 酸性真菌プロテアーゼ
US10829748B2 (en) Mutant lipase and use thereof
Feng et al. Codon optimization of the calf prochymosin gene and its expression in Kluyveromyces lactis
US10450554B2 (en) Proline specific endoprotease
WO2015177153A1 (fr) Endoprotéase spécifique de la proline
WO2015150532A1 (fr) Endoprotéase spécifique de la proline
EP3152304B1 (fr) Endoprotéase spécifique de la proline et son utilisation
WO2015177152A1 (fr) Endoprotéase spécifique de la proline
US7776581B2 (en) Method of producing an aspartic protease in a recombinant host organism
Vishwanatha Acid protease from Aspergillus oryzae: Structure-stability and enhancement of the activity by physical, chemical and molecular biological approaches
Feng et al. Improved secretory production of calf prochymosin by codon optimization and disruption of PMR1 in Kluyveromyces lactis GG799
JPWO2019069977A1 (ja) アルカリホスファターゼの製造方法及びそれを用いて得られるアルカリホスファターゼ、並びにその製造のためのベクター及び形質転換体
Xue et al. Expression and Biochemical Characterization of a Novel Aspartic Protease from Trichoderma Asperellum for the Preparation of Duck Blood Peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15723936

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15723936

Country of ref document: EP

Kind code of ref document: A1